Leishmaniasis are antropozoonosis considered as a serious problem of public health, that represent a complex of diseases with important clinical spectrum and epidemiological diversity. The current treatments are not totally effective and possess serious side effects to patients. Furthermore, in some parts of the world there are reports of resistance of the parasite to standard drugs, that warming to the necessity for finding new therapeutic alternatives to this pathology. In this concern, our group demonstrated that ursólico acid showed therapeutic activity in experimental tegumentar and visceral leishmaniasis. Thus, in order to increasing its efficacy, this project aims at loading the ursolic acid, as well as other three triterpenes in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). The triterpenes will be commercially purchased and loaded into SLN and NLC. The cytotoxic potential and the activity against promastigotes and intracellular amastigotes of triterpene-loaded nanoparticles as well as free triterpenes will be evaluated. The most selective formulation will be chosen to perform in vivo studies, that will be carried out with hamsters infected by L. chagasi. Studies of toxicity with the most selective formulation will be performed. Of note, this is the first study about the development of nanosystems of distribution containing triterpenoids to the treatment of visceral leishmaniasis.
News published in Agência FAPESP Newsletter about the scholarship: